moxonidine has been researched along with Disease Models, Animal in 29 studies
moxonidine: structure given in first source
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " were randomly allocated into three groups as group 1= control group, group 2=subarachnoid hemorrhage (SAH) alone group, and group 3=SAH + moxonidine (treatment) group." | 7.80 | Beneficial effects of moxonidine on cerebral vasospasm after experimental subarachnoid hemorrhage. ( Esen, H; Ilik, MK; Koc, O; Kocaogullar, Y, 2014) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "The aim of the present study was to investigate the influence of moxonidine, a representative of I1-imidazoline-receptor agonist, on arrhythmias induced by myocardial ischemia or reperfusion." | 7.69 | Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. ( Leprán, I; Papp, JG, 1994) |
| "The centrally antihypertensive drug moxonidine decreases ROS production in the RVLM through inactivation of the PI3K/Akt signaling pathway in hypertension." | 3.83 | Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats. ( Hu, QK; Tan, X; Wang, WZ; Wang, YK; Wu, ZT; Yang, YH; Yu, Q; Yuan, WJ; Zhang, RW, 2016) |
| " were randomly allocated into three groups as group 1= control group, group 2=subarachnoid hemorrhage (SAH) alone group, and group 3=SAH + moxonidine (treatment) group." | 3.80 | Beneficial effects of moxonidine on cerebral vasospasm after experimental subarachnoid hemorrhage. ( Esen, H; Ilik, MK; Koc, O; Kocaogullar, Y, 2014) |
| "6 hamsters (6 and 10 months old, with moderate and advanced heart failure, respectively) received moxonidine at 2 concentrations: low (2." | 3.77 | Functional and molecular effects of imidazoline receptor activation in heart failure. ( Abdel Rahman, AA; Aceros, H; Mukaddam-Daher, S; Noiseux, N; Stabile, AM; Stockmeyer, K, 2011) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| " Using radiotelemetry for monitoring cardiovascular parameters of spontaneously hypertensive rats treated with clonidine or moxonidine, we showed that clonidine, unlike moxonidine, resulted in rebound hypertension after drug withdrawal." | 3.69 | Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. ( Dhalla, KS; Dhalla, NS; Rupp, H, 1994) |
| "The aim of the present study was to investigate the influence of moxonidine, a representative of I1-imidazoline-receptor agonist, on arrhythmias induced by myocardial ischemia or reperfusion." | 3.69 | Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. ( Leprán, I; Papp, JG, 1994) |
| "Moxonidine (4-chloro-N-(4, 5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine, BDF 5895) reduces blood pressure and heart rate in rats with genetic hypertension (SHR/Okamoto) and in rats with renovascular hypertension (Goldblatt 1 k/1 c)." | 3.67 | General pharmacology of the novel centrally acting antihypertensive agent moxonidine. ( Armah, BI; Hofferber, E; Stenzel, W, 1988) |
| "Moxonidine also has beneficial effects in animal models of diabetes and kidney disease." | 2.41 | Moxonidine: some controversy. ( Doggrell, SA, 2001) |
| "Treatment with moxonidine, NDDCT and TBZ significantly attenuated 3-NPA induced reduction in body weight, locomotor activity, grip strength, anxiety as well as impaired learning and memory." | 1.40 | Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. ( Gupta, S; Sharma, B, 2014) |
| "Clonidine treatment also reduced arterial pressure and increased functional capillary density in the skin and skeletal muscle of WKY." | 1.36 | Microvascular effects of centrally acting antihypertensive drugs in spontaneously hypertensive rats. ( Bousquet, P; Lessa, MA; Nascimento, AR; Sabino, B; Tibiriçá, E, 2010) |
| "Moxonidine was found to have an U-shape neuroprotective effect in glutamate-induced neurotoxicity in neuronal cell culture experiments." | 1.35 | Protection in glutamate-induced neurotoxicity by imidazoline receptor agonist moxonidine. ( Bakuridze, K; Baş, DB; Gepdiremen, A; Gongadze, N; Savli, E, 2009) |
| "Moxonidine is an antihypertensive imidazoline compound that reduces blood pressure primarily by central inhibition of sympathetic outflow and by direct actions on the heart to release atrial natriuretic peptide, a vasodilator and an antihypertrophic cardiac hormone." | 1.35 | Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation. ( Danalache, B; DeBlois, D; Duguay, D; El-Ayoubi, R; Gutkowska, J; Menaouar, A; Mukaddam-Daher, S; Paquette, PA, 2008) |
| " Similar responses were observed after oral dosing and in lean littermates." | 1.32 | The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X. ( Ernsberger, P; Velliquette, RA, 2003) |
| "Using a rat model of metabolic syndrome X, we sought to separate the influence of these two receptors on glucose and lipid metabolism by using selective antagonists." | 1.32 | The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. ( Ernsberger, P; Koletsky, RJ; Velliquette, RA, 2003) |
| "Pretreatment with moxonidine (0." | 1.31 | Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats. ( Kallman, MJ; Rasmussen, K; Vandergriff, J, 2000) |
| "Moxonidine has been shown to be antiarrhythmic during ischaemia in vivo." | 1.30 | Facilitation of spontaneous defibrillation by moxonidine during regional ischaemia in an isolated working rabbit heart model. ( Cobbe, SM; Hicks, MN; Kane, KA; Wolk, R, 1999) |
| "Moxonidine treatment enhanced the expression of IRS-1 protein in skeletal muscle by 74% in SHROB and 40% in SHR." | 1.30 | Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats. ( Bedol, D; Ernsberger, P; Farrell, CJ; Friedman, JE; Ishizuka, T; Koletsky, RJ; Liu, S, 1998) |
| "Moxonidine is a centrally acting antihypertensive with a selective action on I1-imidazoline receptors in RVLM." | 1.29 | Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. ( Dreshaj, I; Ernsberger, P; Haxhiu, MA; Schäfer, SG, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.45) | 18.7374 |
| 1990's | 9 (31.03) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 7 (24.14) | 24.3611 |
| 2020's | 2 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Łukawski, K | 1 |
| Czuczwar, SJ | 1 |
| Gupta, S | 1 |
| Sharma, B | 1 |
| Ilik, MK | 1 |
| Kocaogullar, Y | 1 |
| Koc, O | 1 |
| Esen, H | 1 |
| Wang, YK | 1 |
| Yu, Q | 1 |
| Tan, X | 1 |
| Wu, ZT | 1 |
| Zhang, RW | 1 |
| Yang, YH | 1 |
| Yuan, WJ | 1 |
| Hu, QK | 1 |
| Wang, WZ | 1 |
| Tanabe, M | 1 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Bakuridze, K | 1 |
| Savli, E | 1 |
| Gongadze, N | 1 |
| Baş, DB | 1 |
| Gepdiremen, A | 1 |
| Nascimento, AR | 1 |
| Lessa, MA | 1 |
| Sabino, B | 1 |
| Bousquet, P | 1 |
| Tibiriçá, E | 1 |
| Stabile, AM | 1 |
| Aceros, H | 1 |
| Stockmeyer, K | 1 |
| Abdel Rahman, AA | 1 |
| Noiseux, N | 1 |
| Mukaddam-Daher, S | 2 |
| Yigiter, M | 1 |
| Yildiz, A | 1 |
| Polat, B | 1 |
| Alp, HH | 1 |
| Keles, ON | 1 |
| Salman, AB | 1 |
| Suleyman, H | 1 |
| Raasch, W | 1 |
| Jungbluth, B | 1 |
| Schäfer, U | 1 |
| Häuser, W | 1 |
| Dominiak, P | 1 |
| Velliquette, RA | 3 |
| Ernsberger, P | 6 |
| Koletsky, RJ | 3 |
| Kossover, R | 1 |
| Previs, SF | 1 |
| Paquette, PA | 1 |
| Duguay, D | 1 |
| El-Ayoubi, R | 1 |
| Menaouar, A | 1 |
| Danalache, B | 1 |
| Gutkowska, J | 1 |
| DeBlois, D | 1 |
| Papp, JG | 2 |
| Ollivier, JP | 1 |
| Rupp, H | 1 |
| Dhalla, KS | 1 |
| Dhalla, NS | 1 |
| Haxhiu, MA | 1 |
| Dreshaj, I | 1 |
| Schäfer, SG | 1 |
| Leprán, I | 1 |
| Glavin, GB | 2 |
| Smyth, DD | 2 |
| Wolk, R | 1 |
| Kane, KA | 1 |
| Cobbe, SM | 1 |
| Hicks, MN | 1 |
| Friedman, JE | 2 |
| Ishizuka, T | 1 |
| Liu, S | 1 |
| Farrell, CJ | 1 |
| Bedol, D | 1 |
| Vandergriff, J | 1 |
| Kallman, MJ | 1 |
| Rasmussen, K | 1 |
| Van Kerckhoven, R | 1 |
| van Veen, TA | 1 |
| Boomsma, F | 1 |
| Saxena, PR | 1 |
| Schoemaker, RG | 1 |
| Doggrell, SA | 1 |
| Armah, BI | 1 |
| Hofferber, E | 1 |
| Stenzel, W | 1 |
1 review available for moxonidine and Disease Models, Animal
| Article | Year |
|---|---|
Moxonidine: some controversy.
Topics: Adrenergic Agonists; Animals; Antihypertensive Agents; Disease Models, Animal; Heart Failure; Humans | 2001 |
28 other studies available for moxonidine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Assessment of drug-drug interactions between moxonidine and antiepileptic drugs in the maximal electroshock seizure test in mice.
Topics: Animals; Anticonvulsants; Antihypertensive Agents; Avoidance Learning; Brain; Disease Models, Animal | 2022 |
Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease.
Topics: Adrenergic Uptake Inhibitors; Animals; Anxiety; Brain; Disease Models, Animal; Ditiocarb; Huntington | 2014 |
Beneficial effects of moxonidine on cerebral vasospasm after experimental subarachnoid hemorrhage.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Imidazoles; Male; Rabbits; Radiography; Ra | 2014 |
Centrally acting drug moxonidine decreases reactive oxygen species via inactivation of the phosphoinositide-3 kinase signaling in the rostral ventrolateral medulla in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzofurans; Disease Models, Animal; Hypertension; Imidazoles; Mal | 2016 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
Protection in glutamate-induced neurotoxicity by imidazoline receptor agonist moxonidine.
Topics: Animals; Animals, Newborn; Cell Count; Cells, Cultured; Disease Models, Animal; Dose-Response Relati | 2009 |
Microvascular effects of centrally acting antihypertensive drugs in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Capillaries; Clonidine; Dise | 2010 |
Functional and molecular effects of imidazoline receptor activation in heart failure.
Topics: Animals; Apoptosis; Blotting, Western; Collagen; Cricetinae; Cytokines; Disease Models, Animal; Dose | 2011 |
The protective effects of metyrosine, lacidipine, clonidine, and moxonidine on kidney damage induced by unilateral ureteral obstruction in rats.
Topics: Acute Kidney Injury; alpha-Methyltyrosine; Animals; Biopsy, Needle; Clonidine; Dihydropyridines; Dis | 2012 |
Modification of noradrenaline release in pithed spontaneously hypertensive rats by I1-binding sites in addition to alpha2-adrenoceptors.
Topics: Adrenergic alpha-Antagonists; Agmatine; Animals; Antihypertensive Agents; Benzofurans; Binding Sites | 2003 |
The role of I(1)-imidazoline and alpha(2)-adrenergic receptors in the modulation of glucose metabolism in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Topics: Adrenergic alpha-2 Receptor Antagonists; Animals; Clonidine; Disease Models, Animal; Female; Glucose | 2003 |
The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X.
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Benzofurans; Blood Pressure; Disease | 2003 |
Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agon | 2006 |
Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation.
Topics: Animals; Antihypertensive Agents; bcl-2-Associated X Protein; Blood Pressure; Caspase 3; Disease Mod | 2008 |
Selective stimulation of I1-imidazoline receptors as a novel mechanism for antihypertensive action. Focus on moxonidine.
Topics: Animals; Antihypertensive Agents; Catecholamines; Death, Sudden; Disease Models, Animal; Heart Arres | 1994 |
Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Blood Pressure; Calcium; Catecholamines; Clo | 1994 |
Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla.
Topics: Adrenergic alpha-Antagonists; Affinity Labels; Animals; Antihypertensive Agents; Benzazepines; Benzo | 1994 |
Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Coronary Vessels; Dise | 1994 |
Moxonidine decreases gastric secretion and gastric mucosal injury in rats.
Topics: Animals; Disease Models, Animal; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Imidazoles; Male; Rat | 1995 |
Effects of the selective I1 imidazoline receptor agonist, moxonidine, on gastric secretion and gastric mucosal injury in rats.
Topics: Analysis of Variance; Animals; Antihypertensive Agents; Clonidine; Disease Models, Animal; Ethanol; | 1995 |
Facilitation of spontaneous defibrillation by moxonidine during regional ischaemia in an isolated working rabbit heart model.
Topics: Action Potentials; Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Disease Models, Animal; E | 1999 |
Anti-hyperglycemic activity of moxonidine: metabolic and molecular effects in obese spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Disease Models, Animal; Female; Hyperglycemia; Hypertension; Hypog | 1998 |
Moxonidine, a selective imidazoline-1 receptor agonist, suppresses the effects of ethanol withdrawal on the acoustic startle response in rats.
Topics: Animals; Antihypertensive Agents; Auditory Perception; Disease Models, Animal; Ethanol; Imidazoles; | 2000 |
Molecular pathology in the obese spontaneous hypertensive Koletsky rat: a model of syndrome X.
Topics: Animals; Anti-Obesity Agents; Carrier Proteins; Disease Models, Animal; Endocrine System; Female; Hy | 1999 |
Chronic administration of moxonidine suppresses sympathetic activation in a rat heart failure model.
Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Collagen; Disease Models, Animal; Dose-Respon | 2000 |
General pharmacology of the novel centrally acting antihypertensive agent moxonidine.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Blood Pressure; Cats; Chemical Phenomena; Ch | 1988 |